3-TYP

Cas No.:	120241-79-4
Chemical Name:	3-(1H-1,2,3-Triazol-4-yl)pyridine
Synonyms:	Pyridine,3-(1H-1,2,3-triazol-5-yl)-;3-(1H-1,2,3-Triazol-4-yl)pyridine;3-TYP;Pyridine, 3-(1H-1,2,3-triazol-4-yl)- (9CI);Pyridine(3-TYP);3-(1H-1,2,3-triazol-5-yl)pyridine;3-(1,2,3-triazol-4-yl)pyridine;3-(1H-1,2,3-triazol-4-yl) pyridine;Pyridine,3-(1H-1,2,3-triazol-4-yl)- (9CI);3-(2H-triazol-4-yl)pyridine;pyridin-3-yl-triazole;BDBM17471;VYXFEFOIYPNBFK-UHFFFAOYSA-N;BCP25686;4-(3-Pyridyl)-1,2,3-triazole;4-(3-Pyridinyl)-1H-1,2,3-triazole;AK204058;3-(2
SMILES:	N1=C(C([H])=NN1[H])C1=C([H])N=C([H])C([H])=C1[H]
Formula:	C7H6N4
M.Wt:	146.1493
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	3-TYP is a selective SIRT3 inhibitor, with an IC50 of 16 nM, more potent over SIRT1 (IC50=88 nM), SIRT2 (IC50=92 nM).
In Vivo:	3-TYP (50 mg/kg, i.p.) does not significantly influence the LVEF, LVFS, infarct size, serum LDH levels, apoptosis, and oxidative stress compared with those of the Sham group. Moreover, 3-TYP has little effect on gp91phox, Nrf2, NQO 1, Bax, Bcl-2, Caspase-3, and cleaved Caspase-3 expression levels, compared with the Sham group. 3-TYP significantly decreases SIRT3 activity and increases the acetylation of SOD2 compared with that in the control group, without influencing SIRT3 expression. 3-TYP attenuates the cardioprotective effects of melatonin by decreasing the LVEF and LVFS after 24 hour of reperfusion. 3-TYP also increases the infarct size, serum LDH levels, and apoptotic ratio compared with those in the IR+Mel group[2].
In Vitro:	3-TYP inhibits melatonin-enhanced SIRT3 activity but does not affect SIRT3 protein expression. 3-TYP pretreatment reverses the protective effects of melatonin on cadmium (Cd)-induced mitochondrial-derived O2•− production and autophagic cell death. 3-TYP significantly attenuates melatonin-induced increases in deacetylated-SOD2 expression and SOD2 activity in HepG2 cells exposed to Cd[1].